Objective Transient receptor potential ankyrin-1 (TRPA1) and transient receptor potential vanilloid-1 (TRPV1) are calcium (Ca 2+ )-permeable ion channels mostly known as pain receptors in sensory neurons. However, growing evidence suggests their crucial involvement in the pathogenesis of IBD. We explored the possible contribution of TRPA1 and TRPV1 to T-cellmediated colitis. Design We evaluated the role of Trpa1 gene deletion in two models of experimental colitis (ie, interleukin-10 knockout and T-cell-adoptive transfer models). We performed electrophysiological and Ca 2+ imaging studies to analyse TRPA1 and TRPV1 functions in CD4+ T cells. We used genetic and pharmacological approaches to evaluate TRPV1 contribution to the phenotype of Trpa1 −/− CD4+ T cells. We also analysed TRPA1 and TRPV1 gene expression and TRPA1 + TRPV1 + T cell infiltration in colonic biopsies from patients with IBD.
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+ TRPV1 + T cell infiltration in colonic biopsies from patients with IBD. Results We identified a protective role for TRPA1 in Tcell-mediated colitis. We demonstrated the functional expression of TRPA1 on the plasma membrane of CD4+ T cells and identified that Trpa1 −/− CD4+ T cells have increased T-cell receptor-induced Ca 2+ influx, activation profile and differentiation into Th1-effector cells. This phenotype was abrogated upon genetic deletion or pharmacological inhibition of the TRPV1 channel in mouse and human CD4+ T cells. Finally, we found differential regulation of TRPA1 and TRPV1 gene expression as well as increased infiltration of TRPA1 + TRPV1
+ T cells in the colon of patients with IBD. Conclusions Our study indicates that TRPA1 inhibits TRPV1 channel activity in CD4+ T cells, and consequently restrains CD4+ T-cell activation and colitogenic responses. These findings may therefore have therapeutic implications for human IBD.
INTRODUCTION
IBDs are initiated by abnormal cell-mediated immune responses, primarily by CD4+ T cells to luminal microbial products in genetically susceptible hosts. 1 The two most common forms of IBD are Crohn's disease (CD) and UC. 1 2 CD is characterised as a T helper (Th) 1-mediated inflammatory response with overproduction of interferon (IFN)-γ and tumour necrosis factor (TNF)-α, whereas UC is considered a Th2-mediated immune disease with massive production of interleukin (IL)-5, IL-9 and IL-13. 2 3 Th17 cells and their related cytokines are also involved in the pathogenesis of CD and UC, but their function is more complex than originally thought as both proinflammatory and tissueprotective effects have been described. 2 4 One of
Significance of this study
What is already known on this subject? What are the new findings?
▸ Trpa1 gene deletion leads to exacerbated T-cell-mediated colitis in mice. ▸ The TRPA1 channel is functionally expressed on the plasma membrane of CD4+ T cells. ▸ TRPA1 inhibits TRPV1 channel activity and consequently restrains T-cell receptor-induced Ca 2+ influx, CD4+ T cell activation and colitogenic responses. ▸ TRPA1 + TRPV1 + T cell infiltration is increased in colonic biopsies of patients with IBD.
How might it impact on clinical practice in the foreseeable future?
▸ The novel functions for TRPA1 and TRPV1 in CD4+ T cells suggest that these two ion channels could represent new therapeutic targets in T-cell-mediated inflammatory diseases such as IBD.
the most advanced therapeutic strategies in patients with IBD is the inhibition of effector CD4+ T cell homing and functions, and hence intestinal inflammation. 5 Despite recent progress in IBD treatment, many current approaches have undesirable side effects and new therapeutic targets aiming to suppress colitogenic CD4+ T cell responses are needed.
Growing evidence suggests that members of the transient receptor potential (TRP) family of ion channels are functionally expressed in immune cells, including T cells. 6 7 Indeed, we recently demonstrated that the transient receptor potential vanilloid-1 (TRPV1) channel is expressed in CD4+ T cells and that it increases their proinflammatory properties in models of colitis. 8 Mechanistically, we identified that TRPV1 contributes to T cell receptor (TCR)-induced calcium (Ca 2+ ) influx and that phosphorylation by the lymphocyte-specific protein tyrosine kinase Lck is a possible gating mechanism for the TRPV1 channel in CD4+ T cells upon TCR stimulation. 8 9 Like other TRPs, the TRPV1 channel functions as a homotetramer and heterotetramer with other TRP channel subunits. 10 Since TRPV1 is predominantly coexpressed with the transient receptor potential ankyrin-1 (TRPA1) channel in sensory neurons [11] [12] [13] and because these two channels can form heterotetrameric channel complexes, [14] [15] [16] we evaluated in the present study TRPA1 function in CD4+ T cells and its potential role in T-cell-mediated colitis.
TRPA1 is a Ca 2+ -permeable cation channel that is involved in various cellular processes. 17 It was originally identified in sensory neurons to respond to noxious cold temperatures (<17°C) and certain pungent compounds such as allyl isothiocyanate (the pungent compound in mustard oil (MO)). 11 18 Since neuronal TRPA1 is activated by a variety of exogenous and endogenous stimuli that cause pain and inflammation, it is considered to play a proinflammatory role. 12 17 19 For example, intracolonic administration of the TRPA1-specific agonist MO or 2,4,6-trinitrobenzene sulfonic acid in mice leads to a severe colitis that is associated with activation of TRPA1 in gut sensory afferent nerves and with the subsequent release of neuropeptides that trigger neurogenic inflammation. 20 21 Here, we report an unexpected anti-inflammatory role for the TRPA1 channel in CD4+ T cells. In contrast to the role of TRPV1, 8 we found that TRPA1 decreases CD4+ T cell activation and proinflammatory properties. Indeed, Trpa1 −/− CD4+ T cells display increased TCR-induced Ca 2+ influx, CD4+ T cell activation and differentiation into Th1-effector cells. As presented below, we identified that TRPA1 restrains TRPV1 channel activity in CD4+ T cells and consequently controls CD4+ T cell activation and proinflammatory responses in two different models of T-cell-mediated colitis. Finally, we observed differential regulation of TRPA1 and TRPV1 gene expression as well as increased infiltration of TRPA1 + TRPV1 + T cells in colonic biopsies of patients with IBD.
RESULTS

TRPA1 deficiency aggravates colitis in Il10
−/− mice To investigate the role of TRPA1 in the development of T-cell-mediated colitis, we crossed Trpa1 −/− mice with the Il10 −/− strain. 22 Between 8 and 10 weeks of age, Il10
−/− Trpa1 −/− mice developed severe spontaneous colitis (ie, body weight loss, diarrhoea, rectal prolapse, shortening and thickening of the colon), whereas Il10 −/− control mice developed very mild disease under the same housing conditions ( figure 1A, B) . The exacerbated colitis in Il10 −/− Trpa1 −/− mice was not transmissible to co-housed Il10 −/− mice and was not likely the result of an altered gut microbiota composition (see online supplementary text and figure S1 ). Histological analysis of Il10
Trpa1
−/− mice colons revealed epithelial hyperproliferation, massive crypt loss and marked infiltration of mononuclear cells in the mucosal layer ( figure 1C ). The gut barrier was also disrupted in these mice as shown by the increased levels of albumin detected in the faeces ( figure 1D ). Consistent with the aforementioned macroscopic alterations in the colon, we found increased transcript levels of proinflammatory cytokines (Ifng, Il17a and Il1b), as well as T cell markers (Cd4 and Cd3d) in colon tissues from Il10 −/− Trpa1 −/− mice ( figure 1E ). Furthermore, ex vivo colonic explants (CEs) from Il10
−/− mice produced significantly higher amounts of IFN-γ compared with Il10 −/− control mice ( figure 1F ). These results indicate that TRPA1 deficiency accelerates the development of colitis and exacerbates intestinal inflammation in this model.
Il10
−/− Trpa1 −/− mice display increased Th1-mediated inflammatory responses
Since the spontaneous colitis in Il10 −/− mice depends predominantly on CD4+ T cells, 23 we analysed their inflammatory profile in Il10 −/− and Il10 −/− Trpa1 −/− mice. Spleens (SP) and mesenteric lymph nodes (MLNs) were enlarged in 12-week-old Il10
Trpa1
−/− mice compared with age-matched Il10 −/− control mice (figure 2A, overview insets). SP and MLN CD4+ T cells isolated from Il10
−/− Trpa1 −/− mice produced significantly higher levels of Th1-type cytokines (IFN-γ and IL-2) compared with those isolated from Il10 −/− mice ( figure 2A, B) . To study the colonic T cells of these mice, we isolated lamina propria lymphocytes (LPLs) and analysed their inflammatory profile by q-PCR. Transcript levels of Ifng and Il2 as well as the transcription factors T-bet, Nfat1 and Nfkb were upregulated in Il10
LPLs compared with Il10
−/− LPLs ( figure 2C ). We next analysed the cytokine production of naive SP CD4+ T cells isolated from 6-week-old mice without clinical signs of colitis. Interestingly, these cells also showed increased IFN-γ and IL-2 production compared with naive CD4+ T cells isolated from age-matched Il10 
Trpa1
−/− mice have an increased proinflammatory profile and a Th1 bias.
Il10
−/− Trpa1 −/− naive CD4+ T cells display exacerbated colitogenic properties
To evaluate whether TRPA1 deficiency in CD4+ T cells was responsible for the phenotype of Il10 −/− Trpa1 −/− mice, we employed the T cell transfer model of colitis. 24 We isolated naive (CD4+CD45RB high CD25 − ) SP T cells from young (6 weeks old), colitis-free, Il10
−/− and Il10
Trpa1 −/− donor mice and adoptively transferred these cells to Rag1 −/− recipient mice. As a control, we co-transferred wild-type C57BL/6 (WT) Tregs (CD4 +CD45RB low CD25+) together with WT-naive CD4+ T cells and monitored the development of the colitis in the different experimental groups. Interestingly, naive CD4+ T cells isolated from Il10 −/− Trpa1 −/− mice induced a significantly greater body weight loss and a higher disease activity index (DAI) in the recipients compared with naive CD4+ T cells isolated from Il10 −/− mice ( figure 3A, B) . As expected, the control group (WT-naive T cells+Treg) did not show any clinical signs of colitis. Histological analysis of the colons confirmed the induction of severe colitis in the recipients of Il10 −/− Trpa1 −/− naive CD4+ T cells, whereas only a mild colitis was observed in the recipients of Il10 −/− naive CD4+ T cells ( figure 3C, D) . The mRNA levels of several proinflammatory markers (eg, Cd4, T-bet, Ifng) were also significantly increased in the colon homogenates of Il10
Trpa1
−/− T cell recipients compared with Il10
−/− T cell recipients ( figure 3E ). Finally, CD4+ T cells isolated both from the spleen and MLN of Il10
−/− T cell recipients produced higher levels of IFN-γ compared with Il10
−/− T cell recipients ( figure 3F ). These results indicate that Il10 −/− Trpa1 −/− CD4+ T cells display increased colitogenic properties and suggest that TRPA1 deficiency in CD4+ T cells is responsible for the exacerbated colitis observed in
CD4+ T cells express a functional TRPA1 channel
To evaluate TRPA1 expression in CD4+ T cells, we isolated spinal cord, SP CD4+ T cells and CD11c + -bone marrow-derived dendritic cells (BMDCs) from WT and Trpa1 −/− mice and analysed Trpa1 mRNA expression by q-PCR. Trpa1 transcripts were found in WT spinal cord and WT CD4+ T cells but not in WT BMDCs or in Trpa1 −/− samples (figure 4A, B). We confirmed TRPA1 protein expression in CD4+ T cells by immunofluorescence staining and identified by confocal microscopy that TRPA1 is mainly expressed at the plasma membrane of CD4+ T cells ( figure 4C ). Indeed, the fluorescence signals of TRPA1 and CD4 (a transmembrane protein) were largely co-localised (Pearson's correlation coefficient, r=0.86) ( figure 4D ).
We next demonstrated TRPA1 channel functionality in CD4 + T cells by recording whole-cell currents evoked by MO (a specific TRPA1 channel agonist) 18 at the holding potential (V holding ) of -60 mV in the perforated patch clamp configuration, which leaves the cell intracellular environment intact. 25 MO-gated currents (I MO ) were recorded in WT CD4+ T cells (10.5±1.2 pA; n=12) but not in Trpa1 −/− CD4+ T cells (1.8±0.3 pA; n=6) or in vehicle-treated WT CD4+ T cells (1.6±0.3 pA; n=5) (figure 5A, B). We confirmed these findings by recording MO-gated currents from pieces of plasma membrane of CD4+ T cells using the cell attached single-channel configuration at V holding = −60 mV (see online supplementary figure S2 ).
Finally, we performed single-cell Ca 2+ imaging to further demonstrate TRPA1 channel functionality in CD4+ T cells. We found that MO significantly increased the intracellular Ca and Il10 −/− mice and was normalised to Gapdh housekeeping gene. The level in the Il10 −/− control group was used as reference and assigned to 1. (F) Proinflammatory cytokine production by colonic explants after 24 hours of culture (ELISA). One representative experiment out of three is shown. Results are expressed as mean±SEM (n=9-10 (A and B) or 6-8 (C-F) mice/group). n.s., not significant; *p<0.05; **p<0.01; ***p<0.001 (two-way analysis of variance with post hoc Bonferroni's test (A) or two-tailed Student's t-test (B-F)). 
Trpa1
−/− and Il10 −/− mice and was normalised to Gapdh housekeeping gene. The level in the Il10 −/− control group was used as reference and assigned to 1. (D) Naïve CD4+ T cells cytokine production. Naive CD4+ T cells were isolated from the spleen of 6-week-old Il10 −/− Trpa1 −/− mice that did not develop colitis yet and did not have any signs of colonic inflammation and from age-matched Il10 −/− control mice. IFN-γ, interleukin (IL)-2, IL-17A and tumour necrosis factor (TNF)-α production was analysed 24 hours after re-stimulation with anti-CD3/28 Abs (ELISA). One representative experiment out of three is shown. Results are expressed as mean±SEM (n=6 (A) or 4 (B-D) mice/group). n.s., not significant; *p<0.05; **p<0.01; ***p<0.001 (two-tailed Student's t-test).
these results indicate that the TRPA1 channel is functionally expressed on the plasma membrane of CD4+ T cells.
−/− CD4+ T cells are hyperactivated and display a Th1 bias
We next evaluated whether Trpa1 gene deletion affects TCR-induced Ca 2+ influx and the subsequent activation of CD4+ T cells. Interestingly, TCR stimulation induced a higher and more sustained Ca 2+ influx in Trpa1 −/− CD4+ T cells compared with WT CD4+ T cells (figure 5E). Similarly to what was observed with ionomycin ( figure 5D ), no differences in Ca 2+ influx were identified between WT and Trpa1 −/− CD4+ T cells following stimulation with the sarcoplasmic reticulum Ca 2+ -ATPase (SERCA) pump inhibitor, thapsigargin (figure 5F), which bypasses proximal TCR signalling and induces store-operated Ca 2+ entry. 26 In line with their increase in TCR-induced Ca 2+ influx and analogous to our observations for Il10 −/− naive CD4+ T cells displayed an increased capacity to differentiate in vitro into Th1 effectors, but not Th17 effectors or Tregs (data not shown), compared with WT-naive CD4+ T cells. We confirmed this increased Th1-cytokine production by using an antigen-specific model and found that Trpa1 −/− OT-II CD4+ T cells stimulated by ovalbumin-loaded WT BMDCs display significantly increased IFN-γ and IL-2 production compared with control (Trpa1 +/+ ) OT-II CD4+ T cells ( figure 6D-F) . Importantly, as observed for Il10
−/− naive CD4+ T cells ( figure 3) , we found that 
−/− naive CD4+ T cells have increased colitogenic properties in vivo (see online supplementary figure S4).
Since visceral afferent sensory neurons and intestinal epithelial cells express functional TRPA1 channels that could affect the severity of the colitis, 20 27-30 we generated Rag1 −/− Trpa1 −/− mice and compared the colitis induced by the transfer of WT-naive CD4+ T cells into Rag1 −/− and Rag1 −/− Trpa1 −/− recipients. We found that both recipient groups had comparable body weight loss, colonic inflammation and displayed similar CD4+ T cell responses (see online supplementary figure S5) . Collectively, these data suggest that cell-intrinsic expression of TRPA1 in CD4+ T cells regulates their activation, their differentiation into Th1-effectors and their colitogenic properties in an adoptive transfer model.
TRPV1 hyperactivation is responsible for the phenotype of
We then investigated the mechanism underlying the phenotype of Trpa1 −/− CD4+ T cells. Since we have previously shown that CD4+ T cells express the TRPV1 channel 8 and because TRPA1 and TRPV1 can regulate each other's activities, [13] [14] [15] [16] we evaluated TRPV1 expression and function in WT and Trpa1 −/− CD4+ T cells. We first performed TRPA1 and TRPV1 double immunofluorescence staining and assessed the potential co-localisation of these two proteins by confocal microscopy.
Interestingly, the staining showed a high degree of TRPA1 and TRPV1 co-localisation at the plasma membrane of WT CD4+ T cells ( figure 7A, B) , suggesting a potential direct interaction between these two channels. However, the expression of Trpv1 mRNA or TRPV1 protein in either total cell lysates (ie, both active and inactive TRPV1 channels) or plasma membrane extracts (ie, active TRPV1 channels) was similar in WT and Trpa1 −/− CD4+ T cells (see online supplementary figure S6 ). In contrast, TRPV1 channel activity was increased in Trpa1 −/− figure 7C , D, the whole-cell perforated patch current evoked by capsaicin (I CAP ), a specific TRPV1 agonist, 31 was significantly increased in Trpa1 −/− CD4+ T cells (18.7±1.9 pA; n=8) compared with WT CD4+ T cells (9.9 ±1.2 pA; n=8). As expected, no I CAP could be recorded in 
CD4+ T cells. As shown in
5E), Trpa1
−/− CD4+ T cells also displayed increased TCR-gated currents compared with WT CD4+ T cells ( figure 7E, F) . Importantly, both genetic deletion and pharmacological inhibition of TRPV1 in Trpa1 
Trpv1
−/− naive CD4+ T cells ( figure 8C-F) .
Finally, to explore the relevance of the data generated in the mouse to the human condition, we performed siRNA-mediated knockdown of TRPA1 and TRPV1 in human primary CD4+ T cells isolated from healthy blood donors. Similarly to our observations with mouse Trpa1 −/− and Trpa1 −/− Trpv1 −/− CD4+ T cells, TRPA1 knockdown increased IFN-γ and IL-2 production by human CD4+ T cells upon stimulation with anti-CD3/28 Abs, and this effect was abolished by double knockdown of TRPA1 and TRPV1 genes (see online supplementary figure S8) . To evaluate the clinical significance of these findings, we analysed TRPA1 and TRPV1 transcript levels in colonic biopsies from patients with IBD. We found that TRPV1 gene expression was significantly downregulated in patients with active UC and CD compared with healthy controls (see online supplementary figure S9 ). Interestingly, TRPA1 gene expression showed the opposite trend and was upregulated in patients with IBD, although the differences observed did not reach statistical significance with the sample size used in this study. To determine whether this effect resulted from a differential infiltration by TRPA1 + and TRPV1 + T cells in the colonic mucosa of patients with IBD, we performed triple immunofluorescence staining of colon sections for TRPA1, TRPV1 and CD3 (see online supplementary text and figure S10). We found that the vast majority of infiltrating CD3 + cells were also TRPA1 + and TRPV1 + (ie, TRPA1 + TRPV1 + T cells) and the number of these cells was significantly increased in the colonic mucosa of both patients with UC and CD compared with control subjects ( figure 9A, B) .
In summary, these results suggest that TRPV1 channel hyperactivation is responsible for the increased TCR-gated currents, the Th1 bias and the exacerbated colitogenic properties of Trpa1 −/− CD4+ T cells. Moreover, the differential regulation of TRPA1 and TRPV1 gene expression and the increased infiltration of TRPA1 + TRPV1 + T cells in inflamed colon sections of patients with UC and CD suggest that TRPA1 and TRPV1 channels may play important roles in the pathogenesis of IBD. 
DISCUSSION
Growing evidence suggests the crucial involvement of the TRPA1 and TRPV1 ion channels in the inflammatory response observed in IBD. 19 27-30 Most studies have focused on the role played by these two channels in peripheral neurons innervating the gut and on their contribution to neurogenic inflammation. However, TRPA1 and TRPV1 have a wide tissue distribution and therefore can play diverse roles in a variety of non-neuronal cells. 17 34 For example, TRPA1 mRNA and protein were detected in many organs and tissues, including brain, heart, small intestine, lung, skeletal muscle, pancreas and spleen. In this study, we demonstrated for the first time the functional expression of TRPA1 in CD4+ T cells. We found that TRPA1 restrains TRPV1 channel activity in CD4+ T cells and consequently limits their activation and differentiation into Th1-effector cells in two different models of T-cell-mediated colitis.
Previous studies have demonstrated a key role for Th1 responses in T-cell-mediated intestinal inflammation, including the colitis development in Il10 −/− mice. 22 35 Indeed, we found that Il10 
Trpa1
−/− mice, Trpa1 −/− and Trpa1 −/− OT-II mice housed under specific pathogen-free conditions do not develop spontaneous colitis, presumably due to proper regulatory T cell function.
In accordance with the higher and more sustained Ca 2+ influx required in Th1 cells compared with other Th subsets, 38 39 we identified that Trpa1 −/− CD4+ T cells have increased TCR-gated currents and subsequently TCR-induced Ca 2+ influx. Furthermore, we found that Trpa1 −/− CD4+ T cells have increased TRPV1 channel activity and that genetic deletion or pharmacological inhibition of TRPV1 in Trpa1 −/− CD4+ T cells (ie, Trpa1 −/− Trpv1 −/− CD4+ T cells and BCTC treatment, respectively) rescued their elevated TCR-gated Ca 2+ currents and their increased Th1 cytokine production. Since BCTC has also been shown to block TRPM8, 40 we have confirmed the data generated with BCTC in vitro and the contribution of TRPV1 to the phenotype of Il10 −/− Trpa1 −/− mice by using another TRPV1 antagonist (ie, SB366791) in vivo. We found that treatment with SB366791 significantly decreased the colitis severity in Il10
−/− mice. However, we could not exclude that inhibition of TRPV1 in other cell types (eg, visceral sensory neurons) and its consequences (eg, inhibition of neuropeptide release) may also have contributed to this effect when SB366791 is given systemically. Therefore, we employed the T-cell-adoptive transfer model to address the effect of cell-intrinsic inhibition of TRPV1 The TRPV1 hyperactivation observed in TRPA1-deficient CD4+ T cells can be achieved by different mechanisms leading to increased (i) TRPV1 mRNA and/or protein expression, (ii) TRPV1 recruitment to the plasma membrane or (iii) TRPV1 phosphorylation that reduces its activation threshold. [41] [42] [43] Our data suggest that TRPV1 hyperactivation is not likely due to increased TRPV1 expression or increased TRPV1 trafficking to the plasma membrane. Therefore, modification of TRPV1 phosphorylation status or TRPV1 quaternary structure (eg, channel multimerisation) might account for the observed TRPV1 channel hyperactivation and the resultant phenotype of Trpa1 −/− CD4+ T cells. In line with this hypothesis, we and others previously reported that TRPA1 and TRPV1 can form heterotetrameric channel complexes [14] [15] [16] in which TRPA1 functionally inhibits TRPV1. 15 Hence, the increased formation of TRPV1 homotetramers in the absence of TRPA1 could potentially result in the increased TRPV1 channel activity observed in Trpa1 −/− CD4+ T cells.
The phenotype of Trpa1 −/− CD4+ T cells is not likely the result of a developmental defect in Trpa1 −/− mice since it was reproduced by knockdown of TRPA1 in primary, mature human CD4+ T cells. Indeed, the increased Th1 cytokine production was also observed after TRPA1 gene knockdown in human primary CD4+ T cells and was abolished by double knockdown of TRPA1 and TRPV1 genes. In addition, we identified reciprocal regulation of TRPA1 and TRPV1 gene expression in colonic biopsies from patients with active IBD. These findings are consistent with previous reports, which showed differential expression of TRPV1 and TRPA1 in inflamed colon sections of patients with IBD. 29 44 45 However, some of these studies suggested an increase in TRPV1 expression by sensory neurons innervating the colon of IBD patients. 44 45 In agreement with our findings, Kun et al recently reported a decrease in TRPV1 expression and an increase in TRPA1 expression in colon biopsies from patients with IBD. Interestingly, the authors of this study also observed strong TRPA1-immunopositivity and TRPV1-immunopositivity within mononuclear cells infiltrating the colonic mucosa of patients with IBD. 29 In line with these observations, we found an increased infiltration of TRPA1 + TRPV1 + T cells in the colonic mucosa of both patients with UC and CD. Collectively, these results suggest that changes in gene expression of TRPA1 and TRPV1 and/or in infiltration of TRPA1 + TRPV1 + T cells in the colon may contribute to the pathophysiology of IBD.
In summary, we demonstrated in this study the functional expression of TRPA1 in CD4+ T cells and reported an unexpected anti-inflammatory role for this channel in T-cell-mediated colitis. These findings therefore challenge the current dogma that TRPA1 plays a detrimental role in inflammatory responses that occur in colitis and suggest that TRPA1 in CD4+ T cells has an opposite function to TRPA1 in visceral sensory neurons. 19 20 27 While neuronal TRPA1 increases acute (eg, neurogenic) inflammation, TRPA1 in CD4+ T cells appears to decrease the severity of chronic (eg, T-cell-mediated) colitis. Our results are in agreement with another recent study reporting a protective role for TRPA1 in colitis 29 and with our previous observations regarding the role of TRPV1 in CD4+ T cell activation and its proinflammatory function. 8 Therefore, additional studies will be necessary to determine the relative contribution of TRPA1 signalling in visceral sensory neurons and in CD4+ T cells, respectively to the pathogenesis of human IBD. Finally, our study further reinforces the idea that Ca 2+ is a critical regulator of T cell inflammatory responses in colitis 46 47 and suggests that Ca 2+ -permeable channels, such as TRPA1 and TRPV1, could represent new therapeutic targets in IBD and potentially in other T-cell-mediated diseases.
MATERIALS AND METHODS
See online supplementary materials.
